Redx Pharma Plc

Equities

REDX

GB00BSNB6S51

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:19 2024-04-26 am EDT			5-day change	1st Jan Change
9 ^GBX	-10.00%		-25.00%	-59.09%

Apr. 19	Redx Pharma shareholders approve AIM delisting plans	AN
Apr. 19	Redx Pharma Gets Shareholder Approval for Delisting from AIM	MT

Redx Pharma shares skyrocket on deal to sell inhibitor program

February 07, 2024 at 06:10 am EST

(Alliance News) - Redx Pharma PLC on Wednesday said it has struck a deal to sell Kirsten rat sarcoma virus inhibitor program to Dublin-based Jazz Pharmaceuticals PLC.

Redx Pharma shares soared 44% to 28.70 pence each in London on Wednesday morning.

The Macclesfield, England-based clinical-stage biotechnology company said it will receive USD10 million upfront, with a potential for up to USD870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales.

Jazz Pharmaceuticals and Redx will collaborate to advance candidates through IND-enabling studies; Jazz Pharmaceuticals will be responsible for all clinical development, regulatory, manufacturing and commercialisation activities.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	JAZZ PHARMACEUTICALS PLC	109.5 USD	+1.89%	-0.44%	6.82B
	REDX PHARMA PLC	9 GBX	-10.00%	-25.00%	43.61M

Latest news about Redx Pharma Plc

Redx Pharma shareholders approve AIM delisting plans	Apr. 19	AN
Redx Pharma Gets Shareholder Approval for Delisting from AIM	Apr. 19	MT
Europe down after Easter holiday weekend	Apr. 02	AN
Redx Pharma plummets on plans to delist from AIM	Apr. 02	AN
FTSE 100 buoyed by UK manufacturing growth	Apr. 02	AN
AIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delist	Apr. 02	AN
Redx Pharma to Delist from London Bourse	Apr. 02	MT
Redx Pharma Doses First Patient in Early-stage Trial of Inflammatory Bowel Disease Treatment	Feb. 28	MT
Redx Announces That First Participant Dosed in Phase 1 Trial of RXC008	Feb. 28	CI
Redx Pharma clarifies not currently pursuing US listing	Feb. 14	AN
Redx Pharma Denies Media Report of Potential US Listing	Feb. 14	MT
Jazz Pharmaceuticals to Acquire Redx Pharma's KRAS Inhibitor Program	Feb. 07	MT
Barratt and Smurfit Kappa bookend FTSE 100	Feb. 07	AN
RedX Pharma to Sell Kirsten Rat Sarcoma Virus Inhibitor Program to Jazz Pharmaceuticals	Feb. 07	MT
Redx Pharma shares skyrocket on deal to sell inhibitor program	Feb. 07	AN
AIM WINNERS & LOSERS: Verditek falls on cash shell plans	Feb. 07	AN
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program	Feb. 07	CI
EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens	Dec. 15	AN
Earnings Flash (REDX.L) REDX PHARMA Posts FY23 Loss GBX-9.90	Dec. 15	MT
Earnings Flash (REDX.L) REDX PHARMA Reports FY23 Revenue GBP4.2M	Dec. 15	MT
Redx Pharma Plc Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 15	CI
Redx Unveils Preclinical Data from New Development Candidate, RXC009	Nov. 06	CI
Redx Pharma plc to Present Preclinical Data on RXC009, A Selective Discoidin Domain Receptor 1 Inhibitor	23-10-30	CI
FTSE 100 Closes Down 1.1% on Middle East Tensions	23-10-18	DJ
Redx Pharma Raises GBP14.1 Million to Advance Clinical Studies	23-10-18	MT

Chart Redx Pharma Plc

Duration

Period

More charts

Company Profile

Redx Pharma Plc is a United Kingdom-based clinical-stage biotechnology company. The Company is focused on the discovering and developing of novel, small molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis. The Companyâs product pipeline includes RXC004, RXC007 (ROCK2 selective inhibitor) and RXC008. RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme Porcupine, a key activator of Wnt-ligands in the Wnt signaling pathway. Selective ROCK2 inhibitor for the treatment of interstitial lung diseases with an initial study in idiopathic pulmonary fibrosis. RXC007 is a potent, selective and orally active inhibitor that targets Rho-Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2), which sits at a nodal point in cell signaling pathways, central to fibrosis. RXC008 for the treatment of fibrostenotic Crohnâs disease.

Sector

Biotechnology & Medical Research

Calendar

2024-06-09 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Redx Pharma Plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.09 GBP

Average target price

1.3 GBP

Spread / Average Target

+1,344.44%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REDX PHARMA PLC	-59.09%	43.61M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs